A Study to Develop a Strategy to Increase Lung Cancer Screening in Women Who May Be at Risk for Lung Cancer
Leveraging Mammography to Identify and Engage Women at Risk for Lung Cancer in Lung Cancer Screening
1 other identifier
interventional
30
1 country
7
Brief Summary
The purpose of this study is to develop a digital strategy to increase awareness about lung cancer screening among women who are eligible to receive it. The digital strategy involves email communications and LungTalk, a web-based (accessed through the Internet) health communication tool that uses text, audio, video, and animation to increase awareness and knowledge about lung cancer screening. This study will focus on women who have recently received a screening mammogram.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for early_phase_1
Started Apr 2021
Longer than P75 for early_phase_1
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 9, 2021
CompletedStudy Start
First participant enrolled
April 9, 2021
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 9, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 9, 2027
May 6, 2026
April 1, 2026
6 years
April 9, 2021
April 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants accrued through digital outreach to identify breast screening participants eligible for lung screening
Develop a proactive digital outreach and engagement strategy to identify breast screening patients who are eligible for lung screening.
6 months
Study Arms (1)
Women who have had a mammogram
EXPERIMENTALParticipants will consist of eligible women who have had a mammogram
Interventions
MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
Eligibility Criteria
You may qualify if:
- LDCT screening-eligible women who received a BiRADS 1 (negative) or 2 (benign/non-cancerous finding) result from a screening mammogram in the last 7 days
- Age 50-80 years
- ≥ 20-pack-year smoking history of combustible cigarettes as per self report
- Women who currently smoke or quit within past 15 years as per self report
- Lung screening naïve as per self-report
You may not qualify if:
- Lung cancer diagnosis
- Chest CT within the last 12 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tali Amir, MD
Memorial Sloan Kettering Cancer Center
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 9, 2021
First Posted
April 19, 2021
Study Start
April 9, 2021
Primary Completion (Estimated)
April 9, 2027
Study Completion (Estimated)
April 9, 2027
Last Updated
May 6, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.